Allakos Inc.: directors' dealings · United States · SEC (Form 4)

About Allakos Inc.

Allakos Inc. is a US-based biotechnology company listed on the Nasdaq (United States) under the ticker ALLK. For French-speaking investors, the name sits in the high-risk, high-optionalité biotech segment: valuation is driven less by current revenues than by clinical data, intellectual-property value, and strategic execution. The company was incorporated in Delaware in March 2012 and has focused on developing antibodies for allergic, inflammatory, and proliferative diseases. Its scientific approach has centered on immunomodulatory receptors found on immune effector cells, with particular emphasis on mast-cell- and siglec-related biology. Operationally, Allakos has historically been a precommercial R&D organization, funded primarily through equity financing rather than product sales. Over time, its pipeline has included several drug candidates, with AK006 most recently the lead program. In January 2025, the company disclosed that AK006 did not demonstrate therapeutic activity in chronic spontaneous urticaria in a Phase 1 study, and management announced the discontinuation of further development of that candidate. That clinical setback materially changed the company’s profile and triggered a broad strategic review aimed at maximizing shareholder value through alternatives such as a merger, asset sale, licensing transaction, or another strategic deal. From a competitive standpoint, Allakos operates in a crowded and scientifically demanding therapeutic area where large pharmaceutical groups and specialized biotech companies are pursuing similar immunology targets. The company’s potential differentiation has been its focus on mechanisms tied to mast-cell activation and eosinophilic biology, but its investment case has been constrained by the absence of a marketed product and by repeated dependence on clinical proof-of-concept. In 2025, Allakos also implemented a major restructuring, including an approximately 75% workforce reduction, reflecting a capital-preservation strategy while it evaluates strategic alternatives. Geographically, Allakos is a United States company with operations based in San Carlos, California, and a regulatory correspondence address in Menlo Park, California. It does not currently present itself as a diversified commercial platform with meaningful international sales; instead, it remains an asset-rich but development-stage biotech with a sharply narrowed operating footprint. Recent highlights that matter to investors include the termination of AK006 development, the restructuring program, the active strategic review, and the company’s ongoing reporting as it navigates a post-clinical-failure transition. In short, ALLK is best understood as a Nasdaq-listed biotech in the United States that has moved from pipeline expansion toward balance-sheet and transaction-driven value realization.